RxDoctor Payments DataLook up a doctor →

Patrick Ott, MD

Medical Oncology · Boston, MANPI 1871792218

Payments from drug & device makers

$4,342,913in general payments, 2019–2025

Across 490 payments — averaging $8863.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.7M
  • E.r. Squibb & Sons, L.L.C.$896K
  • Genentech, Inc.$298K
  • AstraZeneca$173K
  • GSK$126K
  • Pfizer$121K
  • plus $61K from 9 others
$3,300in research payments, 2019–2025

Across 2 payments — averaging $1650.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$3K
  • Eli Lilly$100

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck328$2,668,610
E.r. Squibb & Sons, L.L.C.82$895,653
Genentech, Inc.14$297,787
AstraZeneca5$173,418
GSK13$126,185
Pfizer9$120,721
F. Hoffmann-la Roche AG9$16,152
Novartis13$15,031
Organon5$9,731
Servier Pharmaceuticals LLC1$8,500
AbbVie4$7,201
Eisai Inc.1$1,875
Eli Lilly2$1,528
Array Biopharma Inc3$292
Foundation Medicine, Inc.1$229

How this compares

$4,342,913 in reported general payments places this provider in the 85th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$40,685
Medicare patients
124
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →